Abstract: Described herein are methods and compositions comprising Wnt5a for the diagnosis and treatment of hematopoietic cancers, and methods of identifying therapeutic compounds for the treatment of hematopoietic cancers.

Abstract: Described herein are methods and compositions comprising Wnt5a for the diagnosis and treatment of hematopoietic cancers, and methods of identifying therapeutic compounds for the treatment of hematopoietic cancers.

Abstract: Described herein are methods and compositions comprising Wnt5a for the diagnosis and treatment of hematopoietic cancers, and methods of identifying therapeutic compounds for the treatment of hematopoietic cancers.

Abstract: The invention is based on the discovery that occurrence of centrosomal abnormalities in cells correlates with the occurrence of cancer, and that the greater the degree of the centrosomal abnormalities, the greater the probability of cancer occurring and the severity of the cancer. The invention includes methods of detecting centrosome abnormalities in tissue samples. It provides new methods for predicting and diagnosing cancer.

Abstract: The invention relates to new expedient and cost-effective assays that are capable of identifying many or all relevant diagnostic and prognostic genetic lesions in cancer or cancer predisposition using multiplex PCR or other nucleic acid amplification or enrichment technology in conjunction with bead microarrays for the purpose of risk-stratifying patients with cancer or cancer predisposition. The new assay methods are referred to herein as BARCODE-MT for Bead ARray COded DEtection of Multiple Targets. These assays are high-throughput, and can be automated for highly accurate diagnoses that can be used to optimize risk-adapted therapy.